Beryl Drugs Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20	Mar ' 19

Sources of funds

Owner's fund

Equity share capital

5.09

5.09

5.09

5.09

5.09

Share application money

-

-

-

-

-

Preference share capital

-

-

-

-

-

Reserves & surplus

2.97

2.20

2.84

2.53

2.43

Loan funds

Secured loans

4.54

5.29

4.34

4.71

3.05

Unsecured loans

-

-

-

-

-

Total

12.61

12.59

12.27

12.33

10.58

Uses of funds

Fixed assets

Gross block

10.64

9.86

9.82

10.10

2.85

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

4.61

3.81

2.49

1.50

0.89

Net block

6.03

6.04

7.33

8.60

1.96

Capital work-in-progress

-

-

0.20

-

6.24

Investments

0.15

0.16

0.12

0.56

0.48

Net current assets

Current assets, loans & advances

11.33

11.62

11.00

7.75

5.89

Less : current liabilities & provisions

4.90

5.24

6.38

4.58

3.99

Total net current assets

6.43

6.39

4.63

3.17

1.91

Miscellaneous expenses not written

-

-

-

-

-

Total

12.61

12.59

12.27

12.33

10.58

Notes:

Book value of unquoted investments

-

-

-

-

0.48

Market value of quoted investments

-

-

-

-

-

Contingent liabilities

2.02

1.36

1.36

0.58

1.08

Number of equity sharesoutstanding (Lacs)

50.72

50.72

50.72

50.72

50.72